Table
2:
Demographic, clinical and immunological/neurological characteristics of
corticosteroid-naive SLE patients with vs. without fatigue.
|
Variables |
Fatigue,
yes |
Fatigue,
no |
p |
|
(n
= 8) |
(n
= 35) |
||
|
Demographics |
|||
|
Age, years |
31.4 (8.7) |
28.1 (8.6) |
0.295 |
|
Female |
8/8 (100%) |
34/35 (97/1%) |
0.814 |
|
Education, years |
13.5 (2.1) |
13.4 (1.9) |
0.948 |
|
Clinical characteristics |
|||
|
Disease duration, months |
17.1 (20.6) |
28.2 (44.2) |
0.407 |
|
Time since SLE diagnosisa,
months |
0.0 (0.0) |
3.9 (20.2) |
0.114 |
|
SLEDAI-2K |
14.0 (6.5) |
11.4 (5.7) |
0.332 |
|
Perfomance Statusb |
0.9 (0.8) |
0.3 (0.5) |
0.032c |
|
Pain, VAS, mm |
42.1 (21.4) |
27.7 (24.0) |
0.108 |
|
Sleep disturbanced |
1.5 (2.0) |
0.7 (1.1) |
0.140 |
|
POMS-Anxiety |
21.3 (8.3) |
12.4 (5.8) |
0.005c |
|
POMS-depression |
23.8 (12.0) |
11.7 (8.4) |
0.009c |
|
Immunological/neurological
markers |
|||
|
Anti-DNA antibody, IU/ml, median (IQR) |
32.5 (9.0 - 79.5) |
102.0 (13.0 - 268.0) |
0.225 |
|
CH50, U/ml, median (IQR) |
12.3 (10.0 - 29.5) |
24.6 (12.6 - 33.1) |
0.225 |
|
Antiphospholipid
antibody, positivee |
2/8 (25.0%) |
12/35 (34.3%) |
0.478 |
|
Interleukin-6, pg/ml
(serum), median (IQR) |
2.3 (0.6 - 5.2) |
3.6 (0.9 - 7.0) |
0.471 |
|
Interleukin-6, pg/ml
(CSF), median (IQR) |
2.46 (1.2 - 6.95) |
7.9 (2.8 - 11.0) |
0.072 |
|
Interleukin-8, pg/ml
(serum), median (IQR) |
13.8 (0.0 - 50.2) |
14.4 (0.0 - 62.9) |
0.852 |
|
Interleukin-8, pg/ml
(CSF), median (IQR) |
41.5 (22.7 - 130.6) |
78.0 (35.7 - 129.5) |
0.537 |
|
Interferon-α, IU/l (serum), median
(IQR) |
0.0 (0.0 - 27.4) |
0.0 (0.0 - 1.0) |
0.210 |
|
Interferon-α, IU/l (CSF), median (IQR) |
0.0 (0.0 - 15.5) |
0.0 (0.0 - 3.0) |
0.236 |
|
IgG index,
positive (normal < 0.70) |
0/6 (0.0%) |
6/31 (19.4%) |
0.561 |
|
Brain MRI, abnormalf |
2/8 (25.0%) |
4/33 (12.1%) |
0.331 |
|
Electroencephalogram, abnormal |
4/8 (50.0%) |
14/33 (42.4%) |
0.500 |
Data are number/number assessed (%), mean (standard
deviation: SD), or otherwise stated.
P
values were determined by Fisher's exact test or Mann - Whitney U-test.
aTime
between being diagnosed with SLE based on ACR criteria (1997) for the first
time and assessment.
bDetermined
using Eastern Cooperative Oncology Group criteria
cSignificant
variables
dTotal
scores from the three sleep-related items in the Hamilton Depression Rating
Scale-17 items
eAntiphospholipid
antibodies include anticardiolipin-b2-glycoprotein-I complex and lupus anticoaglant.
fAll
detected abnormalities consisted of small focal lesions (ø < 10 mm) in the
white matter.
VAS = Visual Analog Scale
SLEDAI-2K = Systemic Lupus Erythematosus
Disease Activity Index 2000
POMS = Profile of Mood State
IQR = Interquartile Range
CSF = Cerebrospinal Fluid